Managing Your Vision: Standards of Care and Support
At a Glance
While there is no universal cure for Retinitis Pigmentosa (RP), maximizing remaining vision is possible by treating secondary complications like macular edema and cataracts. Care also focuses on low-vision rehabilitation, occupational therapy, and protecting the eyes with UV sunglasses.
While there is currently no universal cure for Retinitis Pigmentosa (RP), the “standard of care” is far from passive. For the majority of patients whose specific genetic mutation does not yet have an FDA-approved gene therapy, medical care focuses on a dual approach: complication management and functional rehabilitation [1][2]. These strategies are designed to maximize the vision you have and ensure you maintain your independence and quality of life.
Treating Secondary Complications
One of the most empowering facts about RP is that some of the vision loss you experience may be reversible or manageable. RP often causes “secondary” eye problems that, if left untreated, can make your vision seem worse than it actually is.
1. Cystoid Macular Edema (CME)
Many people with RP develop CME, which is a buildup of fluid (swelling) in the central part of the retina [3]. This fluid can cause blurriness or distortion in your central vision.
- Treatment: The first line of defense is usually a class of medication called carbonic anhydrase inhibitors (CAIs), such as acetazolamide (taken as a pill) or dorzolamide (taken as eye drops) [4][5]. These medications help “pump” the fluid out of the retina, often leading to improved central clarity [6].
2. Cataracts
Patients with RP often develop a specific type of cataract (clouding of the lens) called a posterior subcapsular cataract at a younger age than the general population [7].
- Treatment: Cataract surgery is generally very effective for RP patients. By removing the cloudy lens and replacing it with a clear artificial one, many patients experience a significant “brightening” and sharpening of their remaining vision [8][9].
3. Charles Bonnet Syndrome (CBS)
As the visual field constricts, some patients experience visual hallucinations known as Charles Bonnet Syndrome (CBS). It is important to know that this is a normal neurological response—the brain’s attempt to ‘fill in the blanks’ of missing vision—and not a psychiatric issue [10].
Functional Rehabilitation
Adapting to vision loss is a sophisticated form of training designed to help you “work around” the blind spots. It involves a multidisciplinary team to ensure your safety and autonomy [11][12].
- Orientation and Mobility (O&M): This specialized training teaches you how to navigate your world safely. It includes learning techniques for walking in low light and, when necessary, the skilled use of a white cane to detect obstacles and curbs [11][13].
- Occupational Therapy (OT): An OT can help you modify your home or workspace—for example, by using high-contrast markings on stairs or improving lighting—to make daily tasks safer and easier [14].
Protection from the Sun
Most specialists highly recommend wearing high-quality UV-protective sunglasses to reduce oxidative stress on the remaining retinal cells. While clinical proof of its effect on the speed of progression is still being studied, protecting the fragile remaining cells from harsh sunlight is an easy and safe preventative measure [12].
Common questions in this guide
Can the vision loss from Retinitis Pigmentosa be reversed?
What is Cystoid Macular Edema (CME) in RP?
Should I get cataract surgery if I have Retinitis Pigmentosa?
Why am I seeing things that aren't there as my RP progresses?
How can a low-vision specialist or occupational therapist help me?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How often should we screen for treatable complications like cataracts and macular edema?
- 2.Is the 'swelling' in my retina (CME) a candidate for oral or topical carbonic anhydrase inhibitors?
- 3.Can you refer me to a low-vision specialist who can help me trial specific assistive technology?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Retinitis Pigmentosa: From Pathomolecular Mechanisms to Therapeutic Strategies.
Vingolo EM, Mascolo S, Miccichè F, Manco G
Medicina (Kaunas, Lithuania) 2024; (60(1)) doi:10.3390/medicina60010189.
PMID: 38276069 - 2
Insight into the role of non-coding RNA in the diagnosis and treatment of retinitis pigmentosa.
Chen JY, Liu WJ, Niu SR, et al.
Non-coding RNA research 2024; (9(1)):44-54 doi:10.1016/j.ncrna.2023.10.011.
PMID: 38075200 - 3
Detection of cystoid macular edema in patients with retinitis pigmentosa based on deep learning.
Hosseini F, Asadi F, Ahmadieh H, et al.
International journal of retina and vitreous 2025; (11(1)):139 doi:10.1186/s40942-025-00762-6.
PMID: 41444668 - 4
Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review.
Bakthavatchalam M, Lai FHP, Rong SS, et al.
Survey of ophthalmology 2018; (63(3)):329-339 doi:10.1016/j.survophthal.2017.09.009.
PMID: 28987613 - 5
Protocol for the treatment of cystoid macular edema secondary to retinitis pigmentosa and other inherited retinal dystrophies.
Català-Mora J, Santamaría Álvarez JF, Kyriakou D, et al.
Archivos de la Sociedad Espanola de Oftalmologia 2024; (99(2)):67-81 doi:10.1016/j.oftale.2023.11.001.
PMID: 37940089 - 6
Carbonic anhydrase inhibitors in the management of macular edema: A review of the literature.
Shahsuvaryan ML
Medical hypothesis, discovery & innovation ophthalmology journal 2022; (11(1)):34-41 doi:10.51329/mehdiophthal1443.
PMID: 37641698 - 7
A Review of Complicated Cataract in Retinitis Pigmentosa: Pathogenesis and Cataract Surgery.
Hong Y, Li H, Sun Y, Ji Y
Journal of ophthalmology 2020; (2020()):6699103 doi:10.1155/2020/6699103.
PMID: 33489339 - 8
Cataract surgery in retinitis pigmentosa.
Karti O, Saatci AO
Medical hypothesis, discovery & innovation ophthalmology journal 2024; (13(2)):96-103 doi:10.51329/mehdiophthal1500.
PMID: 39206084 - 9
Cataract surgery in patients with retinitis pigmentosa: systematic review.
Khojasteh H, Riazi-Esfahani H, Mirghorbani M, et al.
Journal of cataract and refractive surgery 2023; (49(3)):312-320 doi:10.1097/j.jcrs.0000000000001101.
PMID: 36730350 - 10
Retinitis Pigmentosa: Pathogenesis, Diagnostic Findings, and Treatment.
Kamde SP, Anjankar A
Cureus 2023; (15(10)):e48006 doi:10.7759/cureus.48006.
PMID: 38034182 - 11
[The Bardet-Biedl Syndrome - Diagnosis and Follow-up].
Rohrschneider K, Bolz HJ
Klinische Monatsblatter fur Augenheilkunde 2020; (237(3)):239-247 doi:10.1055/a-1118-3748.
PMID: 32182628 - 12
Retinitis Pigmentosa: Novel Therapeutic Targets and Drug Development.
Wu KY, Kulbay M, Toameh D, et al.
Pharmaceutics 2023; (15(2)) doi:10.3390/pharmaceutics15020685.
PMID: 36840007 - 13
Vision rehabilitation of patients with retinitis pigmentosa.
Shah M, Tariq Y
Clinical & experimental optometry 2026; (109(2)):215-220 doi:10.1080/08164622.2025.2522178.
PMID: 40690992 - 14
A 5-year retrospective record review of hospital-based low-vision rehabilitation in Thailand.
Chotikavanich S, Chanvarapha N, Loket S, et al.
Clinical optometry 2018; (10()):41-50 doi:10.2147/OPTO.S160103.
PMID: 30214341
This page provides information on standard care and rehabilitation for Retinitis Pigmentosa. It is for educational purposes only and does not replace professional advice from your ophthalmologist or low-vision specialist.
Get notified when new evidence is published on Retinitis pigmentosa.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.